XML 15 R5.htm IDEA: XBRL DOCUMENT v3.21.2
Condensed Consolidated Statements of Stockholders Equity (Deficit) - USD ($)
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Deficit [Member]
Noncontrolling Interest [Member]
Preferred Stock [Member]
Series B Preferred Stock [Member]
Series B Preferred Stock [Member]
Total
Balance at Dec. 31, 2019 $ 17,000 $ 232,580,000 $ (235,537,000) $ (2,878,000) $ 4,761,000   $ (1,057,000)
Balance (in shares) at Dec. 31, 2019 16,806,430       7,638    
Stock-based compensation $ 0 83,000 0 0 $ 0   83,000
Series A Preferred Stock Dividends 0 0 (62,000) 0 0   (62,000)
Issuance of SYN Biomics Stock $ 0 0 0 26,000 $ 0   26,000
Conversion of Series B Preferred Stock to Common (in shares) 933,045       (1,073)    
Conversion of Series B Preferred Stock to Common $ 1,000 1,072,000 (404,000) 0 $ (669,000)   0
Net loss 0 0 (2,964,000) 0 0   (2,964,000)
Non-controlling interest 0 0 0 (26,000) 0   (26,000)
Balance at Mar. 31, 2020 $ 18,000 233,735,000 (238,967,000) (2,878,000) $ 4,092,000   (4,000,000)
Balance (in shares) at Mar. 31, 2020 17,739,475       6,565    
Balance at Dec. 31, 2019 $ 17,000 232,580,000 (235,537,000) (2,878,000) $ 4,761,000   (1,057,000)
Balance (in shares) at Dec. 31, 2019 16,806,430       7,638    
Net loss             (7,934,000)
Non-controlling interest           $ 100,000 (50,000)
Balance at Sep. 30, 2020 $ 20,000 236,320,000 (244,975,000) (2,750,000) $ 2,584,000   (8,801,000)
Balance (in shares) at Sep. 30, 2020 19,842,955       4,146    
Balance at Mar. 31, 2020 $ 18,000 233,735,000 (238,967,000) (2,878,000) $ 4,092,000   (4,000,000)
Balance (in shares) at Mar. 31, 2020 17,739,475       6,565    
Stock-based compensation $ 0 86,000 0 0 $ 0   86,000
Series A Preferred Stock Dividends 0 0 (63,000) 0 0   (63,000)
Issuance of SYN Biomics Stock $ 0 0 0 10,000 $ 0   10,000
Conversion of Series B Preferred Stock to Common (in shares) 904,349       (1,040)    
Conversion of Series B Preferred Stock to Common $ 1,000 1,039,000 (392,000) 0 $ (648,000)   0
Net loss 0 0 (2,867,000) 0 0   (2,867,000)
Non-controlling interest 0 0 0 (16,000) 0   (16,000)
Balance at Jun. 30, 2020 $ 19,000 234,860,000 (242,289,000) (2,884,000) $ 3,444,000   (6,850,000)
Balance (in shares) at Jun. 30, 2020 18,643,824       5,525    
Stock-based compensation $ 0 82,000 0 0 $ 0   82,000
Series A Preferred Stock Dividends 0 0 (64,000) 0 0   (64,000)
Issuance of SYN Biomics Stock $ 0 0 0 142,000 $ 0   142,000
Conversion of Series B Preferred Stock to Common (in shares) 1,199,131       (1,379)    
Conversion of Series B Preferred Stock to Common $ 1,000 1,378,000 (519,000) 0 $ (860,000)   0
Net loss 0 0 (2,103,000) 0 0   (2,103,000)
Non-controlling interest 0 0 0 (16,000) 0 100,000 (8,000)
Balance at Sep. 30, 2020 $ 20,000 236,320,000 (244,975,000) (2,750,000) $ 2,584,000   (8,801,000)
Balance (in shares) at Sep. 30, 2020 19,842,955       4,146    
Balance at Dec. 31, 2020 $ 29,000 240,821,000 (248,094,000) (2,773,000) $ 2,477,000   (7,540,000)
Balance (in shares) at Dec. 31, 2020 29,249,925       3,973    
Stock-based compensation $ 0 101,000 0 0 $ 0   101,000
Stock issued under "at-the-market" offering $ 79,000 65,881,000 0 0 0   65,960,000
Stock issued under "at-the-market" offering (in shares) 78,685,315            
Warrants Exercised $ 12,000 8,030,000 0 0 0   8,042,000
Warrants Exercised (In shares) 11,655,747            
Series A Preferred Stock Dividends $ 0 0 (24,000) 0 0   (24,000)
Effect of Series A Preferred Stock price adjustment $ 0 7,402,000 (7,402,000) 0 $ 0   0
Conversion of Series B Preferred Stock to Common (in shares) 3,454,783       (3,973)    
Conversion of Series B Preferred Stock to Common $ 3,000 3,971,000 (1,497,000) 0 $ (2,477,000)   0
Conversion of Series A Preferred Stock to Common $ 9,000 12,813,000 0 0 $ 0   12,822,000
Conversion of Series A Preferred Stock to Common (in shares) 8,996,768       0    
Net loss $ 0 0 (2,536,000) 0 $ 0   (2,536,000)
Non-controlling interest 0 0 0 (1,000) 0   (1,000)
Balance at Mar. 31, 2021 $ 132,000 339,019,000 (259,553,000) (2,774,000) $ 0   76,824,000
Balance (in shares) at Mar. 31, 2021 132,042,538       0    
Balance at Dec. 31, 2020 $ 29,000 240,821,000 (248,094,000) (2,773,000) $ 2,477,000   (7,540,000)
Balance (in shares) at Dec. 31, 2020 29,249,925       3,973    
Net loss             (9,004,000)
Non-controlling interest           $ 100,000 (1,000)
Balance at Sep. 30, 2021 $ 132,000 339,223,000 (266,021,000) (2,774,000) $ 0   70,560,000
Balance (in shares) at Sep. 30, 2021 132,042,538       0    
Balance at Mar. 31, 2021 $ 132,000 339,019,000 (259,553,000) (2,774,000) $ 0   76,824,000
Balance (in shares) at Mar. 31, 2021 132,042,538       0    
Stock-based compensation $ 0 102,000 0 0 $ 0   102,000
Net loss 0 0 (3,195,000) 0 0   (3,195,000)
Balance at Jun. 30, 2021 $ 132,000 339,121,000 (262,748,000) (2,774,000) $ 0   73,731,000
Balance (in shares) at Jun. 30, 2021 132,042,538       0    
Stock-based compensation $ 0 102,000 0 0 $ 0   $ 102,000
Warrants Exercised (In shares)             0
Net loss 0 0 (3,273,000) 0 0   $ (3,273,000)
Non-controlling interest             0
Balance at Sep. 30, 2021 $ 132,000 $ 339,223,000 $ (266,021,000) $ (2,774,000) $ 0   $ 70,560,000
Balance (in shares) at Sep. 30, 2021 132,042,538       0